# Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors

> **NCT06031480** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 55 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Anlotinib and TQB2450

## Key facts

- **NCT ID:** NCT06031480
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-31
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2023-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06031480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06031480, "Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06031480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*